Literature DB >> 19898503

Effect of missing killer-immunoglobulin-like receptor ligand in recipients undergoing HLA full matched, non-T-depleted sibling donor transplantation: a single institution experience of 151 Asian patients.

Y C Linn1, C Y Phang, T J Lim, S F Chong, K K Heng, J J Lee, Y Loh, W Hwang, Y T Goh, M Koh.   

Abstract

This retrospective analysis studied the impact of natural killer (NK) alloreactivity based on the missing ligand model, for a cohort of recipients undergoing haemopoietic stem cell transplant without T-cell depletion from HLA full-matched sibling donors. All patients received a uniform myeloablative conditioning regimen and prophylaxis for GVHD. A total of 151 patients were studied, including 62 patients with AML or myelodysplastic syndrome, 42 patients with ALL and 47 patients with CML. We found that 81% of patients had at least one missing KIR-ligand (KIR-L), and HLA-C1 allogroup homozygosity is present in 70% of patients. From multivariate analysis, we observed that the only consistently significant factor that was associated with superior survival was disease stage. Missing KIR-L, whether considering HLA-Bw and HLA-C alleles, without or with HLA-A ligands or narrowing to only HLA-C alleles alone to classify the number of missing KIR-L, did not have any impact on OS or relapse-free survival. This negative finding implies that as the KIR-L composition of recipient is not important in this matched non-T-depleted setting, further immunotherapeutic measures involving adoptive NK cell infusions have to be explored to exploit the benefit of NK alloreactivity for such transplants.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19898503     DOI: 10.1038/bmt.2009.303

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.

Authors:  Wei Wang; Amy K Erbe; Mikayla Gallenberger; KyungMann Kim; Lakeesha Carmichael; Dustin Hess; Eneida A Mendonca; Yiqiang Song; Jacquelyn A Hank; Su-Chun Cheng; Sabina Signoretti; Michael Atkins; Alexander Carlson; Jonathan M Weiss; James Mier; David Panka; David F McDermott; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2016-09-30       Impact factor: 6.968

Review 2.  Influence of KIR and NK Cell Reconstitution in the Outcomes of Hematopoietic Stem Cell Transplantation.

Authors:  Fei Gao; Yishan Ye; Yang Gao; He Huang; Yanmin Zhao
Journal:  Front Immunol       Date:  2020-09-02       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.